---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-122434"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T08:20:56.546323+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Enanta sells 54.5% of MAVYRET royalties to OMERS for $200M; non-dilutive funding

## Summary
- Sold 54.5% of future royalty payments on MAVYRET/MAVIRET worldwide sales to OMERS Life Sciences for $200M.
- OMERS receives royalty payments from July 2023 through June 2032, capped at 1.42x purchase price ($284M).
- Enanta retains 45.5% of royalties until cap is reached, then 100% reverts to Enanta.
- Proceeds to fund clinical development of pipeline therapies for viral infections; transaction is non-dilutive.

## SEC filing metadata
- accession: 0001193125-23-122434
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000119312523122434/0001193125-23-122434-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000119312523122434/d500394d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-122434
- JSON: https://secwatch.observer/filing/0001193125-23-122434.json
- Plain text: https://secwatch.observer/filing/0001193125-23-122434.txt

## Key facts
- Material Agreements
  ENANTA PHARMACEUTICALS INC entered into Royalty Purchase Agreement with OCM Life Sciences Portfolio LP, an investment vehicle of OMERS valued at $200 million (effective 2023-04-25).
  - Action: entry
  - Counterparty: OCM Life Sciences Portfolio LP, an investment vehicle of OMERS
  - Value: $200 million
  - Effective: 2023-04-25
  source text: On April 25, 2023, Enanta Pharmaceuticals, Inc. and OCM Life Sciences Portfolio LP, an investment vehicle of OMERS, one of Canada’s largest defined benefit pension plans, entered into a Royalty Purchase Agreement (the “ Agreement ”), pursuant to which Enanta sold to OMERS 54.5% of Enanta’s royalty interest in respect of worldwide net sales of MAVYRET ® /MAVIRET ® (and any other royalty-bearing products that may contain glecaprevir). The purchase price paid to Enanta was $200 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1177648/000119312523122434/0001193125-23-122434-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.